KROS

Keros Therapeutics, Inc.

• NASDAQ·04/03 15:30

  Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

• NASDAQ·03/31 06:46

  Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

• Reuters·03/11 20:38

  Keros Therapeutics Inc Files Initial Beneficial Ownership Statement for Director Charles W. Newton

• Reuters·03/11 20:37

  Keros Therapeutics Director Jean Jacques Bienaime Acquires Common Shares

• TipRanks·03/10 20:35

  Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks

• TipRanks·03/10 10:41

  Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL)

• TipRanks·03/09 12:32

  Keros Therapeutics Advances Rinvatercept in ALS Collaboration

• TipRanks·03/09 12:17

  Keros Therapeutics presents additional data from Phase 1 of rinvatercept

• Benzinga·03/09 12:10

  Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference

• Reuters·03/09 12:00

  KEROS THERAPEUTICS ANNOUNCES COLLABORATION WITH SEAN M. HEALEY & AMG CENTER FOR ALS

• TipRanks·03/09 07:50

  Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Azitra Inc (AZTR)

• TipRanks·03/06 14:36

  Keros Therapeutics (KROS) Receives a Buy from Leerink Partners

• TipRanks·03/06 06:01

  Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility

• TipRanks·03/05 17:10

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Climb Bio (CLYM) and Sight Sciences (SGHT)

• Dow Jones·03/05 16:47

  Keros Therapeutics Price Target Cut to $20.00/Share From $23.00 by Wells Fargo